The layoffs, which will affect people in sales-related positions, come as a Los Angles lawyer investigates the marketing and sales practices Avanir used to push its key drug Nuedexta.
Two months ago, Los Angeles City Attorney Mike Feuer launched a probe into Avanir to determine if the pharmaceutical company violated state or federal laws by aggressively targeting elderly patients in its marketing and selling of Nuedexta, which has not been extensively studied in the elderly.
Nuedexta is FDA approved to treat pseudobulbar affect, which is a rare condition marked by uncontrollable laughing and crying that affects less than 1 percent of Americans. However, a recent CNN report found Nuedexta’s financial success was instead propelled by a sales team pushing physicians to prescribe the drug to elderly patients suffering from dementia and Alzheimer’s. The CNN report details instances where the drugmaker paid physicians large sums of money to prescribe the drug.
More articles on supply chain:
FDA warns of a new product shortage worsened by Hurricane Maria: 4 things to know
Gilead launches hepatitis drug in China at one-fifth the US price
CVS launches ‘real-time benefits’ tool to increase price transparency
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
